RxDoctor Payments DataLook up a doctor →

Winston Dunn, MD

Gastroenterology · Kansas City, KSNPI 1801869656

Payments from drug & device makers

$2,222,619in general payments, 2019–2025

Across 384 payments — averaging $5788.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$1M
  • Gilead$632K
  • AbbVie$215K
  • Madrigal Pharmaceuticals$201K
  • Intercept Pharma Europe Ltd.$107K
  • Novo Nordisk$44K
  • plus $15K from 8 others
$78in research payments, 2019–2025

Across 1 payment — averaging $77.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$78

What the payments were for

  • Consulting fees$20,78412%
  • Speaking & faculty fees$120,24971%
  • Travel & lodging$21,80313%
  • Food & beverage$5,7523%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,222,619 in reported general payments places this provider in the 95th percentile of 98 gastroenterology providers in Kansas.

See all gastroenterology providers in Kansas

Medicare billing

Part B allowed, 2024
$54,466
Medicare patients
263
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin245$785,558
EpclusaSofosbuvir/Velpatasvir12$285,345
OzempicSemaglutide30$42,565
Tacrolimus291$22,436
VemlidyTenofovir Alafenamide15$20,481
Ursodiol99$20,370
EliquisApixaban21$18,546
JanuviaSitagliptin Phosphate24$13,338
FarxigaDapagliflozin Propanediol11$12,474
Mycophenolic AcidMycophenolate Sodium91$8,977
Entecavir60$6,098
JardianceEmpagliflozin11$5,712
Envarsus XrTacrolimus13$3,751
Budesonide EcBudesonide14$3,733
Cyclosporine ModifiedCyclosporine, Modified42$3,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$39$785,558245 claims
GileadEpclusa, Vemlidy$632,142$305,82627 claims
Novo NordiskOzempic$44,041$42,56530 claims
AstraZenecaFarxiga$1,477$12,47411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 gastroenterology providers in Kansas.

Other gastroenterology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →